UROCAP
TAMSULOSIN HCI USP
| NAME | STRENGTH | PACK SIZE | DOSAGE FORM |
|---|---|---|---|
| UROCAP 0.4 CAPSULE | 0.4 MG | 30 S | CAPSULE |
Each capsule contains Tamsulosin HCI USP 0.4 mg as modified release pellets.
Tamsulosin HCI 0.4 mg capsule is used to treat men who have symptoms of an enlarged prostate gland, which is also known as Benign Prostatic Hyperplasia (BPH). Tamsulosin, an alpha-blocker, is indicated for the treatment of the signs and symptoms of BPH. Tamsulosin works by relaxing the muscles in the bladder and prostate.
Tamsulosin HCI is indicated in the treatment of functional symptoms of Benign Prostatic Hyperplasia (BPH).
The first dose when starting tamsulosin hydrochloride is 0.4 mg by mouth once daily. The dose may be increased after 2 to 4 weeks, if necessary, to tamsulosin hydrochloride 0.8 mg (two 0.4 mg capsules) once daily. If tamsulosin HCI administration is discontinued or interrupted for several days at either the 0.4 mg or 0.8 mg dose,therapy should be started again with the 0.4 mg tamsulosin HCI.
Tamsulosin HCI is contraindicated in those patients who shows hypersensitivity to any component of this.
Rarely, transient postural symptoms have occured during orthostatic provocation testing after the first dose. Use in patients with micturition syncope is not advised.
The following common side effects have been reported during the use of tamsulosin: dizziness, abnormal ejaculation and less frequently headache, asthenia, postural hypotension, palpitations.
Not applicable as Tamsulosin HCI is intended for male patients only.
Concurrent administration of other a, adrenoceptor antagonists could lead to hypotensive effects. No interactions have been reported when tamsulosin was given concomitantly with either atenolol, enalapril or nifedipine. No interactions at the level of hepatic metabolism have been seen during in vitro studies with liver microsomal fractions (representative of the cytochrome P450-linked drug metabolising enzyme system), involving amitriptyline, salbutamol, glibenclamide and finasteride. Diclofenac and warfarin, however, may increase the elimination rate of tamsulosin.
No case of acute overdosage have been reported. However, acute hypotension is likely to occur after overdosage in which case cardiovascular support should be given.
Store in a cool and dry place. Keep away from light and out of reach of children.
Each box contains 3x10's capsules of Tamsulosin HCI USP 0.4 mg in blister pack.